NCT01933672 - Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

PF-04937319 once-daily

Tablets, 300 mg once-daily with breakfast, 14-days

DRUG

PF-04937319 split-dose

tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days

DRUG

Sitagliptin once-daily

tablets, 100 mg once-daily with breakfast, 14-days

Trial Locations (8)

High Point Clinical Trials Center, LLC, High Point

Avail Clinical Research, LLC, DeLand

Miami Research Associates, Inc., South Miami

MRA Clinical Research, LLC, South Miami

Community Research, Cincinnati

Spaulding Clinical Research, LLC, West Bend

Clinical Trials of Texas, Inc, San Antonio

Diabetes and Glandular Disease Clinic, San Antonio